Adverse Occurrence type:
Alerting signals, symptoms, evidence of occurrence:
None. Occurring on days of injections
Demonstration of imputability or root cause:
Definite/probable. Temporal relationship to GCSF.
Spleen enlargement following recombinant human granulocyte colony-stimulating factor administration for peripheral blood stem cell mobilization
Clinical and ultrasonic evaluation of spleen size during peripheral blood progenitor cell mobilization by filgrastim: results of an open-label trial in normal donors
Short and long-term safety of lenograstim administration in healthy peripheral haematopoietic progenitor cell donors: a single centre experience